A phase 1/2 trial of TH9619 in colorectal cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by One-carbon Therapeutics AB, now recruiting.
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07151040 by One-carbon Therapeutics AB, with 43 participants planned, started 2025-08-22 and due to reach its primary completion in 2026-12. Interventions recorded: TH9619.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.